Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725046 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3ALDH1A1MAPT | |
| SCHEMBL3725047 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3ALDH1A1MAPT | |
| SCHEMBL31588379 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3ALDH1A1MAPT | |
| SCHEMBL30686153 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL29397862 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL29445591 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL2304915 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL3724885 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL2304920 | 0.89 | MDM2 (0.59) | MDM4TP53CASP3MDM2PTPN1 | |
| SCHEMBL12522498 | 0.89 | MDM4 (0.53) | MDM4TP53CASP3MDM2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| US-11807660-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2023-11-07 | — | — | US | disclosed |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
| US-20220213142-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PROTAGONIST THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, NPY1R | MDM4 4245/4885TP53 2133/4885CASP3 1418/4885 |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1009/4885TP53 127/4885CASP3 1714/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 3040/4885TP53 421/4885CASP3 1560/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1149/4885TP53 154/4885CASP3 1646/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1128/4885TP53 158/4885CASP3 1798/4885 |
| US-20220185846-A1 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS | PSMA7, ITGB7, SCN7A | MDM4 2020/4885TP53 4405/4885CASP3 3125/4885 |
| US-20220213142-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | KISS1R, VIP, SSTR3 | MDM4 3063/4885TP53 1696/4885CASP3 535/4885 |
| US-11807660-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, SSTR3 | MDM4 3063/4885TP53 1696/4885CASP3 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.